Original Source(s)
Related Content
FDA approves first therapy for symptomatic dermographism
The oral BTK inhibitor produced a complete hive response in 29.3% of treated patients at week 12.
by Teraya Smith
October 7, 2026
-
2 min
FDA grants Temab-A dual Breakthrough status
The designations cover refractory metastatic CRC and previously treated c-Met–expressing NSCLC.
by Mouj Hijazi
October 7, 2026
-
3 min
